US-based CooperSurgical has partnered with Fulgent Genetics to provide exclusive newborn genetic screening panels to families of the CBR.

The collaboration leverages Fulgent's Picture Genetics platform to offer a suite of genetic testing options through CBR, a private newborn stem cell preservation company and a CooperSurgical brand.

Fulgent Genetics chief commercial officer Brandon Perthuis said: “Partnering with CBR allows us to help provide more families with actionable information about their newborn's health.

“Part of our mission is to use our resources and testing to improve the lives of those around us. Newborn genetic analysis serves as an illustration of this commitment, as early intervention may significantly improve health outcomes for many of these conditions."

The testing options include CBR Snapshot, which screens for more than 250 genes related to various disorders in children where early detection could be crucial.

CBR Portrait expands on this by screening for over 600 genes, including those related to rare conditions.

The most comprehensive test, CBR Landscape, screens for more than 1,500 genes and includes a pharmacogenetic component to predict medication metabolism and potential adverse reactions.

All these Picture Genetic tests are made available exclusively to CBR clients and evaluate genes associated with conditions potentially treatable with newborn stem cells.

CoperSurgical president Holly Sheffield said: “We are proud to offer our CBR families additional resources that complement our newborn stem cell services as we continue to deliver personalised, cutting-edge solutions to families nationwide.”

A wholly-owned subsidiary of CooperCompanies, CooperSurgical is engaged in producing and marketing products and services for use by women's health care clinicians.

Last year, CooperCompanies acquired certain medical device assets, focused primarily on Doppler monitoring, obstetrics and gynaecology surgery markets, from Cook Medical.